Compare QMCO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMCO | BDTX |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.1M | 104.0M |
| IPO Year | 2025 | 2020 |
| Metric | QMCO | BDTX |
|---|---|---|
| Price | $30.34 | $1.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $26.50 | $10.00 |
| AVG Volume (30 Days) | ★ 1.6M | 590.7K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 64.34 | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $372,827,000.00 | N/A |
| Revenue This Year | $18.93 | N/A |
| Revenue Next Year | $13.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.65 | N/A |
| 52 Week Low | $4.19 | $1.60 |
| 52 Week High | $35.65 | $4.94 |
| Indicator | QMCO | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 39.45 |
| Support Level | $5.54 | $1.79 |
| Resistance Level | N/A | $1.90 |
| Average True Range (ATR) | 3.07 | 0.08 |
| MACD | -0.34 | -0.01 |
| Stochastic Oscillator | 51.03 | 20.00 |
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.